Multi-omics Mendelian randomization to identify novel immune therapeutic targets in benign prostatic hyperplasiaOA
Benign prostatic hyperplasia(BPH)is the most common benign condition associated with lower urinary tract symptoms in aging males,significantly impacting their quality of life.Accumulating evidence suggests that BPH is intricately associated with chronic inflammation.With the availability of large-scale Genome-Wide Association Study(GWAS)data and advancements in analysis methods,we investigated the causal relationship between the immune-related genes and BPH using multi-omics quantitative trait loci data.Notably,butyrophilin subfamily 3 member A2(BTN3A2)emerged as a priority level 1 candidate gene,demonstrating consistent correlations with BPH across all analytical levels.The identification of BTN3A2-associated mechanisms provides novel insights into tissue-specific immune modulation in BPH management.
Zhenpeng Zhu;Xing Ji;Wenyuan Leng;Weimin Hu;Chunru Xu;Xiaoyu Li;Jinqin Qian;Cuijian Zhang;Jian Lin
Department of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,ChinaDepartment of Urology,Peking University First Hospital,Beijing 100034,China Institute of Urology,Peking University,Beijing 100034,China National Urological Cancer Center,Beijing 100034,China Beijing Key Laboratory of Urogenital Diseases(Male)Molecular Diagnosis and Treatment Center,Beijing 100034,China
医药卫生
Benign Prostatic HyperplasiaImmune Therapeutic Targetsbenign conditionMendelian Randomizationbenign prostatic hyperplasia bphlower urinary tract symptomsanalysis methodsweMulti omics
《Genes & Diseases》 2026 (4)
P.79-82,4
supported by grants from the National Natural Science Foundation of China(No.82500819,82270708)Shenzhen Medical Research Fund(Guangdong,China)(No.A2302040).
评论